Passali, Desiderio
Arezzo, Maria Felice
De Rose, Alessandra
De Simone, Gianmarco
Forte, Gianluigi
Jablko-Musial, Michalina
Mösges, Ralph
Article History
Received: 10 December 2021
Accepted: 3 June 2022
First Online: 17 June 2022
Declarations
:
: The study was carried out in accordance with the European Data Protection Rules with informed consent from all participants. According to the article 1, paragraph 1, of the legislative decree n. 211 of 2003 (legislation implementing the European Directive 2001/20 / EC on the application of good clinical practice in the execution of clinical trials of medicinal products for clinical use) and according to the Sect. 1.3 of the EphMRA (European Pharmaceutical Market Research Association) Code of Conduct, no formal ethics approval was needed since no research on human tissue or other biological material was performed, as stated by the research marketing company that conducted the survey. The participating general practitioners and pharmacists were informed about the use and publication of their anonymized data for this study. Participation in the study was voluntary. Returning the completed questionnaire was interpreted as informed consent to participate in the study. No incentives were offered.
: Not applicable.
: Prof. Dr. Mösges reports personal fees from Angelini Pharma, during the conduct of the study; personal fees from ALK, grants from ASIT biotech, personal fees from allergopharma, personal fees from Allergy Therapeutics, grants and personal fees from Bencard, grants from Leti, grants, personal fees and non-financial support from Lofarma, non-financial support from Roxall, grants and personal fees from Stallergenes, grants from Optima, personal fees from Friulchem, personal fees from Hexal, personal fees from Servier, personal fees from Klosterfrau, non-financial support from Atmos, personal fees from Bayer, non-financial support from Bionorica, personal fees from FAES, personal fees from GSK, personal fees from MSD, personal fees from Johnson&Johnson, personal fees from Meda, personal fees and non-financial support from Novartis, non-financial support from Otonomy, personal fees from Stada, personal fees from UCB, non-financial support from Ferrero, grants from BitopAG, grants from Hulka, personal fees from Nuvo, grants and personal fees from Ursapharm, personal fees from Menarini, personal fees from Mundipharma, personal fees from Pohl-Boskamp, grants from Inmunotek, grants from Cassella-med GmbH & Co. KG, personal fees from Laboratoire de la Mer, personal fees from Sidroga, grants and personal fees from HAL BV, personal fees from Lek, personal fees from PRO-AdWise, outside the submitted work.Passali D., Arezzo M. F., De Rose A., De Simone G., Forte G., Jablko-Musial M. declares no conflict of interest.